Introduction {#s1}
============

Gastric cancer is the fourth most common malignancy and second leading cause of cancer death in the world [@pone.0086097-Brenner1]. Even screening programs with barium photofluorography or endoscopy allow earlier detection in Japan and Korea, the patients with advanced gastric cancer are still worse in 5-year overall survival. Identifying molecular aberrations in gastric cancer may improve our understanding of gastric carcinogenesis, identify strategies for subdividing patients into relevant subgroups, and highlight novel molecular target agents. Although the molecular mechanisms of gastric cancer carcinogenesis remain unclear, both genetic and epigenetic alterations are important. Genetic alterations are responsible for activation of onceogenes and inactivation of tumor-suppressor gene. Epigenetic alteration through DNA methylation is known to play an important role in inhibiting the expression of tumor-related genes.

Aberrant DNA methylation in cancer was summarized as global hypomethylation and regional hypermethylation, which are associated with genomic instability and inactivation of tumor-suppressor genes, respectively [@pone.0086097-Park1]. However, regional hypermethylation refers to the aberrant methylation of normally unmethylated sequences, most of which are clusters of CpG sites, denoted CpG island. Because multiple genes are concurrently methylated in the hypermethylated subtype, CIMP concept was first introduced to the molecular pathways of colorectal cancers by Dr. Issa group [@pone.0086097-Toyota1]. After that, Scientists have found that CIMP-positive colorectal cancers have a close association with the molecular and clinicopathological features, and poor prognosis [@pone.0086097-Jo1]--[@pone.0086097-Pai1].

Similarly, the presence of CIMP-positive gastric cancer has been reported by many scientists [@pone.0086097-Oue1]--[@pone.0086097-Liu1], but controversial data did not confirm the prognostic value of CIMP for gastric cancer. This was possibly due to small sample size or confounding variables. Therefore, we initiated an international collaborative effort which resulted in a meta-analysis of data on individual patient in prospective cohort studies to evaluate the association between CIMP and malignant behavior in gastric cancer.

Methods {#s2}
=======

Publication Search {#s2a}
------------------

Two electronic databases (PubMed and Embase) were searched (last search was updated on 21 November 2012, using the search terms: 'Gastric cancer' and 'CIMP'. All eligible studies were retrieved, and their bibliographies were checked for other relevant publications. Review articles and bibliographies of other relevant studies identified were hand-searched to identify additional eligible studies. Only published studies with full-text articles were included. When the same patient population was included in several publications, only the most recent or complete study was used in this meta-analysis.

Inclusion Criteria {#s2b}
------------------

The inclusion criteria were as follows: (a) evaluating the relation between CIMP and H. *pylori*, EBV, MSI or clinical prognostic parameters; (b) promoter methylation; and (c) sufficient published data to estimate an odds ratio (OR) with 95% confidence interval (CI).

Data Extraction {#s2c}
---------------

Information was carefully extracted from all eligible studies by two of the authors (Zong L and Seto Y), according to the inclusion criteria listed above. The following data were collected from each study: first author\'s surname, publication date, study method, sample size, total number of patients with positive CIMP and negative CIMP, and number of patients divided by age, gender, tumor site, pathological type, cell differentiation, TNM stage, lymph node metastasis, distant metastasis and 5-year overall survival in those with and without CIMP, respectively. We did not define a minimum number of patients for inclusion in our meta-analysis.

Statistical Analysis {#s2d}
--------------------

Odd ratios with 95% CI were used to assess the correlation of CIMP with H. *pylori*, EBV, and MSI and prognosis, according to the method of Woolf. Heterogeneity assumption was confirmed by the X^2^-based Q-test. A P-value greater than 0.10 for the Q-test indicated a lack of heterogeneity among the studies, therefore, the OR estimate for each study was calculated by the fixed-effects model. Otherwise, the random-effects model was used. The significance of the pooled OR was determined by the Z-test and P\>0.05 was considered statistically significant. Sensitivity analyses were carried out to determine if modification of the inclusion criteria for this meta-analysis affected the final results. An estimate of potential publication bias was carried out using the funnel plot, in which the OR for each study was plotted against its log (OR). An asymmetric plot suggested possible publication bias. Funnel plot asymmetry was assessed using Egger\'s linear regression test, a linear regression approach to measure funnel plot asymmetry on the natural logarithm scale of the OR. The significance of the intercept was determined by the t-test, as suggested by Egger (P\<0.05 was considered representative of statistically significant publication bias). All statistical tests were performed with Review Manager Version 5.0 (The Cochrane Collaboration, Oxford, England).

Results {#s3}
=======

Study Characteristics {#s3a}
---------------------

A total of 18 publications met the basic inclusion criteria [@pone.0086097-Oue1]--[@pone.0086097-Liu1]. The study by Oue *et al* was excluded because they did not categorized into CIMP subgroups with methylated gene panel [@pone.0086097-Oue1]. In addition, the study by Kanai *et al* was excluded because they focused on DNA methylation of CPG islands and pericentromeric satellite regions in colorectal and stomach cancer [@pone.0086097-Kanai1]. Similarly the study by Oshimo *et al* was excluded because they mainly analyzed the relation between epigenetic inactivation of RIZ1 and CIMP [@pone.0086097-Oshimo1]. The study by Watanabe *et al* was not included because they tried to prove fidelity in replicating DNA methylation patterns in cancer cells lead to dense methylation of a CpG island [@pone.0086097-Watanabe1]. Other studies were excluded due to insufficient information to calculate OR [@pone.0086097-Toyota2], [@pone.0086097-Zouridis1]. Hence, a total of 12 studies including 1000 patients were used in the pooled analyses. [Table 1](#pone-0086097-t001){ref-type="table"} lists the studies identified and their main characteristics. Of the 12 groups, sample size ranged from 40 to 200 ([Figure 1](#pone-0086097-g001){ref-type="fig"}).

![Flow chart of literature selection.](pone.0086097.g001){#pone-0086097-g001}
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###### Main characteristics of all studies included in the meta-analysis.

![](pone.0086097.t001){#pone-0086097-t001-1}

  Study              Study Period    N       Study Method       CpG island site                                                      Gene type                                                                              Cut off value                                                                                     Features
  ----------------- -------------- ----- --------------------- ----------------- ----------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  Kim *et al*            2003       200           MSP              Promoter                                            MINT1, MINT2, MINT12, MINT25, MINT31                                         CIMP-high (3--5), CIMP-intermediate (2), CIMP-low (1 or less)                                              MSI-H GC was related to the high CIMP.
  An *et al*             2005       82    MSP microdissection      Promoter                                             MINT1, MINT2, MINT25, MINT31, MLH1                                          CIMP-high (3 or more), CIMP-low (2 or less), CIMP-negative (0)                                   CIMP-high GC was associated with MSI and better prognosis.
  Kim *et al*            2005       40            MSP              Promoter                                       hMLH1, MINT2, TIMP3, THBS1, DAP-K, GST P1, APC                                         CIMP-high (3--7), CIMP-low(1--2), CIMP-negative (0)                                             There were no specific findings for CIMP-high GC.
  Oue *et al*            2006       75           COBRA             Promoter                                            MINT1, MINT2, MINT12, MINT25, MINT31                                                      CIMP+ (3 or more), CIMP− (2 or less)                                                      There were no specific findings for CIMP+ GC.
  Chang *et al*          2006       91            MSP              Promoter                                                LOX, HRASLS, FLNc, HAND1, TM                                             CIMP-high (4--5), CIMP-intermediate (1--3), CIMP-negative (0)                                        CIMP-high GC was associated with better prognosis.
  Kusano *et al*         2006       78           COBRA             Promoter                                            MINT1, MINT2, MINT12, MINT25, MINT31                                         CIMP-high (4--5), CIMP-intermediate (1--3), CIMP-negative (0)    CIMP-high GC was closely associated with proximal location, diffuse type, less-advanced tumor stage, and better prognosis.
  Enomoto *et al*        2007       66            MSP              Promoter                         LOX, HRASLS, FLNc, HAND1,THBD, F2R, NT5E, GREM1, ZNF177, CLDN3, PAX6, CTSL                        CIMP-high (5 or more), CIMP-low (1--4), CIMP-negative (0)                             CIMP-high GC was closely associated with diffuse type and better prognosis.
  Zhang *et al*          2008       47            MSP              Promoter                                              hMLH1, MINT1, MINT2, MINT31, p16                                           CIMP-high (3--5), CIMP-intermediate (1--2), CIMP-negative (0)                                        There were no specific findings for CIMP-high GC.
  Kondo *et al*          2009       41            MSP              Promoter                             hMLH-1, MINT1, MINT2, MINT31, Kip2, p16, p15, p73, MGMT, DAPK, HCAD                                      CIMP+ (4 or more), CIMP− (3 or less)                            H. *pylori* infection caused the aberrant DNA hypermethylation of specific genes and induced CIMP.
  Park *et al*           2010       150     MethyLight PCR         Promoter       BCL2, BDNF, CACNA1G, CALCA, CHFR, CYP1B1, DLEC1, GRIN2B, RUNX3, SEZ6L, SFRP4, TERT, THBS1, TIMP3, TP73, TWIST1.       CIMP-high (14--16), CIMP-low (1--3), CIMP-negative (0)                                             CIMP-high GC was featured with poor prognosis.
  Chen *et al*           2012       120     MethyLight PCR         Promoter                                             ALX4, TMEFF2, CHCHD10, IGFBP3, NPR1                                              CIMP-high (4--5), CIMP-low (1--3), CIMP-negative (0)                                   CIMP-high GC was associated with more distant lymph node metastasis.
  Liu *et al*            2012       72            MSP              Promoter                                          APC, WIF1, RUNX3, DLC1, SFRP1, DKK, E-cad                                                   CIMP+ (3 or more), CIMP− (2 or less)                  H. *pylori*+/CIMP+ cases were associated with higher rates of metastasis and recurrence than H. *pylori*+/CIMP− cases.

COBRA, combined bisulfite restriction analysis; CIMP, CpG island methylator phenotype; GC, gastric cancer; MSP, methylation-specific PCR; Q-MSP, quantitative MSP.

Correlation with Virus Infection and Molecular Stability {#s3b}
--------------------------------------------------------

The overall OR for H. *pylori* infection in CIMP positive group *vs.* negative group revealed that significantly elevated risks of positive H. *pylori* infection in the former were achieved (OR 2.23 95% CI, 1.25--4.00;P = 0.007, P~heterogeneity~ = 0.05). Similarly, strong relation between EBV infection and CIMP was achieved by OR 51.27 (95% CI, 9.39--279.86; P\<0.00001, P~heterogeneity~ = 0.39). The overall OR for MSI in CIMP positive group *vs.* negative group was 4.44 (95% CI, 1.17--16.88; P = 0.03, P~heterogeneity~ = 0.01) ([Table 2](#pone-0086097-t002){ref-type="table"} and [Figure 2](#pone-0086097-g002){ref-type="fig"}).

![CIMP+ *vs.* CIMP−: a) H. *pylori*; b) EBV; c) MSI.](pone.0086097.g002){#pone-0086097-g002}
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###### Outcomes of the meta-analysis.

![](pone.0086097.t002){#pone-0086097-t002-2}

  Parameters               No. Studies   Sample Size   Heterogeneity            OR             95% CI of Overall Effect        P        
  ----------------------- ------------- ------------- --------------- ----------------------- -------------------------- -------------- ------------
  H. *pylori*                   5            137            243        P = 0.05, I^2 = ^58%              2.23              1.25--4.00    P = 0.007
  EBV                           2            40             104         P = 0.39, I^2 = ^0%             51.27             9.39--279.86   P\<0.00001
  MSI                           4            136            306        P = 0.01, I^2 = ^71%              4.44             1.17--16.88     P = 0.03
  Age                           4            87             195         P = 0.52, I^2 = ^0%              1.10              0.63--1.93     P = 0.74
  Gender                        9            184            565         P = 0.91, I^2 = ^0%              0.69              0.48--1.00     P = 0.05
  Tumor site                    4            85             206        P = 0.17, I^2 = ^40%              0.85              0.51--1.44     P = 0.55
  Pathological type             7            142            440        P = 0.03, I^2 = ^56%              0.63              0.31--1.28     P = 0.20
  Cell differentiation          3            45             264         P = 0.68, I^2 = ^0%              0.64              0.29--1.42     P = 0.27
  TNM stage                     4            47             212        P = 0.08, I^2 = ^56%              1.39              0.54--3.57     P = 0.49
  Distant metastasis            4            103            258        P = 0.004, I^2 = ^77%             1.69              0.37--7.67     P = 0.49
  Lymph node metastasis         6            128            349        P = 0.16, I^2 = ^37%              0.81              0.50--1.31     P = 0.39
  5-year survival               2            32             114        P = 0.02, I^2 = ^82%              0.65             0.04--10.70     P = 0.76

CIMP, CpG island methylator phenotype; CI, confidence interval; EBV, Epstein-Barr virus; H. *pylori*, *Helicobacter pylori*; MSI, microsatellite instability; OR, odds ratio.

Correlation with Clinical Information {#s3c}
-------------------------------------

The meta-analysis of both age distribution and gender in the CIMP-positive *vs.* -negative groups did not attain statistical significance (OR 1.10 95% CI, 0.63--1.93; P = 0.74, P~heterogeneity~ = 0.52) and (OR 0.69 95% CI, 0.48--1.00; P = 0.05, P~heterogeneity~ = 0.91). The overall OR for tumor site in the CIMP-positive *vs.* -negative subgroups was 0.85 (95% CI, 0.51--1.44; P = 0.55, P~heterogeneity~ = 0.17). The overall OR for either pathological type or cell differentiation in the CIMP-positive *vs.* -negative subgroups did not show any positive finding (OR 0.63 95% CI, 0.31--1.28; P = 0.20, P~heterogeneity~ = 0.03 and OR 0.64 95% CI, 0.29--1.42; P = 0.027, P~heterogeneity~ = 0.68, respectively) ([Table 2](#pone-0086097-t002){ref-type="table"} and [Figure 3](#pone-0086097-g003){ref-type="fig"}).

![CIMP+ *vs.* CIMP−: a) Age; b) Gender; c) Tumor site; d) Pathological type; e) Cell differentiation.](pone.0086097.g003){#pone-0086097-g003}

Correlation with Prognostic Parameters {#s3d}
--------------------------------------

Although some studies reported that CIMP may correlate with a better prognosis in gastric cancer, no matter on TNM stage, distant metastasis, lymph node metastasis, or even 5-year survival rate, CIMP did not have any significant correlation with one of them in our analysis ([Table 2](#pone-0086097-t002){ref-type="table"} and [Figure 4](#pone-0086097-g004){ref-type="fig"}).

![CIMP+ *vs.* CIMP−: a) TNM stage; b) Distant metastasis; c) Lymph node metastasis; d) 5-year survival.](pone.0086097.g004){#pone-0086097-g004}

Publication Bias {#s3e}
----------------

Begg\'s funnel plot was performed to assess publication bias. The heterogeneity tests for comparing the 12 combined studies showed heterogeneity in some analyses such as MSI, pathological type, distant metastasis and 5-year survival. However, no single study influenced the pooled OR qualitatively as indicated by the sensitivity analyses (data not shown).

Discussion {#s4}
==========

Epigenetic alterations have been suggested to be significant initiating events in cancerization [@pone.0086097-Feinberg1]. However, with the deep involvement of aberrant DNA methylation in human cancers becoming clear, the occasional presence of aberrant DNA methylation in non-cancerous tissues was recognized in the Barrett\'s esophagus [@pone.0086097-Eads1], stomach [@pone.0086097-Waki1], colon [@pone.0086097-Issa1], [@pone.0086097-Hsieh1], and liver [@pone.0086097-Kondo2], which suggested the involvement of the former in the field for cancerization. Chronic inflammation, possibly specific types is likely to induce aberrant DNA methylation in normal tissues and thus form an "epigenetic field for cancerization". To supply the evidence, it is well known that chronic inflammation plays an important role in ulcerative colitis for colon cancers, chronic hepatitis for liver cancers, and Barrett\'s esophagus for esophagus cancers. Infection by H. *pylori* is known to induce severe chronic inflammation, which were involved in the induction of the field for gastric cancers. In addition, aberrant DNA methylation in gastric biopsies from H. *pylori* ^+^ patients was found to be correlated with a greater gastric cancer risk in several studies [@pone.0086097-Niwa1], [@pone.0086097-Nakajima1]. Therefore, aberrant DNA methylation might be the key event in tumor genesis of gastric cancer.

In last decade, careful quantitative evaluation showed that many genes that are highly methylated in carcinoma also show a low but measurable degree of methylation in normal mucosa [@pone.0086097-Rashid1]. Furthermore, aberrant methylated region focusing in the promoter rich in CpG islands suggested the key step in epigenetic gene silencing. It is therefore necessary to elucidate the methylation statuses of a panel of representative genes in an individual disease. To achieve this goal, CpG island methylator phenotype was introduced by Toyota *et al* [@pone.0086097-Toyota1]. Till now, it was well evidenced that CIMP is associated with poor prognosis in colorectal cancer, lung cancer and neuroblastoma. Although the term "CIMP" has been used in a variety of ways in the context of gastric cancer [@pone.0086097-Kusano1], its prognostic value in gastric cancer is still controversial. For example, An *et al.* showed that CIMP, which correlated with malignant features on histopathology, was an independent prognostic factor for overall and cause-specific survival in patients with gastric cancer [@pone.0086097-An1], whereas Kim *et al.* and Zhang *et al.* failed to observe such an association [@pone.0086097-Kim2], [@pone.0086097-Zhang1]. Park *et al.* suggested that CIMP-high GCs were featured with characteristic clinicopathological parameters, including poor prognosis [@pone.0086097-Park2]. However, in contrast, Chang *et al.* and Kusano *et al.* suggested that CIMP-high showing better prognosis [@pone.0086097-Chang1], [@pone.0086097-Kusano1]. Some scientists supposed this discrepancy might come from using different CIMP marker panels as the determination of CIMP status; however, there was a common point of these studies in which the methylated cite of CIMP marker genes lied in promoter. Therefore, it still represents a trend of methylation level in promoter, by which the CIMP is meaningful in tumorigenesis of gastric cancer. In our opinion, prospective data was less convincing mainly due to small sample size and the lack of statistical power to integrate sporadic individual studies.

With the goal to explore the potential value of CIMP in gastric cancer, we performed this meta-analysis of published studies to derive an overall pooled estimation. Since some studies have divided patients into three groups, CIMP-high, CIMP-immediate, CIMP-low, we combine the latter two into CIMP-negative subtype in comparison with no changed CIMP-high as CIMP-positive subtype. From [table 2](#pone-0086097-t002){ref-type="table"}, our findings strongly suggested that H. *pylori* and EBV infections cause the aberrant DNA hypermethylation of specific genes and induce CIMP, an important epigenetic mechanism of the tumorigenesis. However, the mechanism for aberrant DNA hypermethylation induced by H. *pylori* might be different from that by EBV. Recent study by Huang *et al.* supported that H. *pylori* infection causes gastric mucosal inflammatory responses, resulting in up-regulation of interleukin-1b (IL-1b) and overproduction of mutagenic nitric oxide (NO), by which aberrant DNA methylation was induced [@pone.0086097-Huang1]. As for EBV infection, it was suggested that the methylation mechanism in host cells might be primarily for defense against foreign DNA and that the host-driven extensive methylation of viral genome may also trigger host genome methylation [@pone.0086097-Kaneda1]. It was also demonstrated repeatedly that direct interaction of viral latent proteins with DNA methyl transferases (DNMT), up-regulation of DNMT genes by viral latent proteins, and increased expression of polycomb group proteins may contribute to alternations in DNA methylation and histone modifications [@pone.0086097-Kaneda1]--[@pone.0086097-Fukayama1].

Furthermore, strong relation of CIMP with MSI reveals that CIMP may have a potential relation with gene mutations, which may cooperate with each other in development and progression of gastric cancer. However, the meta-analysis did not show any correlations with clinical parameters such as age, gender, tumor site, pathological type, cell differentiation, TNM stage, distant metastasis, lymph node metastasis, and 5-year survival.

If CIMP was a key incidence in gastric cancer, the reason why the CIMP in promoter could not be used as a prognostic marker is not clear. It is possible that gene methylation in promoter lead to the primary tumor genesis but not progressing in gastric cancer. However, another possible reason is that limited methylated CpG island sites do not represent the true trend of CIMP. Regardless of the above analysis, heterogeneity is also one of the important sources that limited us to make more precise conclusion. Therefore, it is essential to develop more extensive large-scale study with bead-array technology in future.
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